Everything You Need to Know About Opsumit Prescribing Information
If you’re a healthcare professional looking to prescribe Opsumit, it’s important to have a clear understanding of the medication’s prescribing information. Opsumit is a prescription medicine used to treat pulmonary arterial hypertension (PAH). In this article, we’ll cover everything you need to know about Opsumit prescribing information.
What is Opsumit?
Opsumit is a prescription medicine that contains the active ingredient macitentan. It’s used to treat pulmonary arterial hypertension (PAH), which is a type of high blood pressure that affects the arteries in the lungs and heart. Opsumit is classified as an endothelin receptor antagonist (ERA), and it works by blocking the effects of endothelin, which is a substance in the body that can cause blood vessels to constrict.
Who can take Opsumit?
Opsumit is indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and to improve exercise capacity. It is approved for use in adults and pediatric patients aged 12 years and older. It is not recommended for pregnant or breastfeeding women.
How is Opsumit taken?
Opsumit is taken once daily with or without food and should be swallowed whole with liquid. The recommended starting dose is 10 mg once daily. After 4-8 weeks of treatment, the dose may be increased to 10 mg once daily depending on the patient’s response. The maximum daily dose is 10 mg.
What are the side effects of Opsumit?
As with any medication, Opsumit may cause side effects. The most common side effects include headache, swelling of the ankles, legs, and feet, nasopharyngitis, upper respiratory tract infection, and anemia. Other less common side effects include decreased appetite, chest pain, shortness of breath, and decreased blood pressure. It’s important to discuss any side effects with your healthcare provider to determine if continuing treatment with Opsumit is appropriate.
What are the precautions and warnings for Opsumit?
Opsumit should be used with caution in patients with severe hepatic (liver) impairment or moderate renal (kidney) impairment. It is not recommended for use in patients with severe renal impairment or end-stage renal disease. It is contraindicated in patients who are pregnant or breastfeeding.
Opsumit may decrease the effectiveness of hormonal contraceptives. Therefore, women of childbearing potential should use two effective forms of contraception when taking Opsumit. Opsumit may also cause fetal harm when administered to pregnant women. Therefore, pregnancy should be avoided during treatment with Opsumit.
Conclusion
In conclusion, Opsumit is a prescription medicine used to treat pulmonary arterial hypertension (PAH). It contains the active ingredient macitentan and is classified as an endothelin receptor antagonist. Opsumit is indicated for use in adults and pediatric patients aged 12 years and older. It’s important to understand the prescribing information, including the dosing and administration, side effects, and precautions and warnings, before prescribing Opsumit to patients. As always, it’s crucial to consult your healthcare provider before starting or changing any medication.
(Note: Do you have knowledge or insights to share? Unlock new opportunities and expand your reach by joining our authors team. Click Registration to join us and share your expertise with our readers.)